We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Novel Hip Resurfacing System Helps Preserve Bone

By HospiMedica International staff writers
Posted on 24 Nov 2009
A new hip resurfacing system is designed to offer pain relief and restoration of function, while retaining as much healthy bone as possible and preserving future surgery options, including a primary total hip replacement. More...


The Conserve Plus Total Hip Resurfacing System contains a femoral and acetabular component configuration and is made of a metal-on-metal cobalt chromium molybdenum alloy. Among the advantages of the Conserve Plus system are conservation and preservation of bone stock, approximation of normal joint physiology and increased range of motion (ROM), improved stability, minimal morbidity, and easy revision (if necessary) since it does not violate the femoral canal. The device ranges in size from 36 mm – 56 mm on the femoral side, comparing favorably in regards to range of motion with traditional 22 mm, 28 mm, and 32 mm femoral heads. The clearance between components is size-dependent and ranges from 90 μ to 200 μ of diametral clearance, each bearing size having an optimized gap for maximum fluid film thickness.

The maximum range of motion with the Conserve Plus system is 167°, compared to 130° with traditional 28 mm heads; this range of motion decreases the likelihood of postoperative dislocation, which is the second leading cause of hip replacement failures.

The Conserve Plus Total Hip Resurfacing System is a product of Wright Medical (Arlington, TN, USA), and has been approved by the U.S. Food and Drug Administration (FDA).

"Hip resurfacing represents a valuable alternative to younger, more active patients who desire a hip reconstruction that more anatomically mimics the natural hip,” said Patrick Fisher, Sr., director of marketing for Wright's hip franchise. "We have learned that this is an option for patients who meet the criteria for hip resurfacing, and these individuals tend to be very enthusiastic and outspoken about their positive results.”

Metal-on-metal articulation devices are typically associated with cobalt-chromium-molybdenum alloy that has a high carbon content (over 0.20%). In addition, two types of processes used in manufacturing the cobalt chrome molybdenum components: casting and forging of the material. Although the chemical composition can be identical between the two materials, there is a structural difference; the grain size of the forged alloy is typically less than 10 μ, whereas the grain size for the cast material ranges from 30 μ to 1000 μ. Tests have shown less wear with cast high carbon alloy than forged alloy, although due to the limited number of samples, the difference has a low statistical reliability.

Related Links:

Wright Medical


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Surgical Headlight
IsoTorch
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.